Detailed dose evidence documented for Thymosin beta-4 in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Not established
No approved labeled regimen
No established or recommended human dose.
None. No Tβ4-containing product has received FDA or EMA approval.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
Ophthalmic: 0.1% RGN-259 (timbetasin acetate) eye drops, one drop per eye, 2-5× daily for 14-28 days in clinical trials.
Systemic: No established systemic regimen has been studied in controlled human trials.
Not established
What is not established
No established or recommended human dose. This applies to systemic use; the ophthalmic candidate and any marketed research material are not interchangeable.